AU2021231327A1 - Protease-processed molecules - Google Patents

Protease-processed molecules Download PDF

Info

Publication number
AU2021231327A1
AU2021231327A1 AU2021231327A AU2021231327A AU2021231327A1 AU 2021231327 A1 AU2021231327 A1 AU 2021231327A1 AU 2021231327 A AU2021231327 A AU 2021231327A AU 2021231327 A AU2021231327 A AU 2021231327A AU 2021231327 A1 AU2021231327 A1 AU 2021231327A1
Authority
AU
Australia
Prior art keywords
immunoglobulin
protein
protease
constant region
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021231327A
Other languages
English (en)
Inventor
Thomas Langer
Ercole Rao
Sandra WEIL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of AU2021231327A1 publication Critical patent/AU2021231327A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021231327A 2020-03-05 2021-03-05 Protease-processed molecules Pending AU2021231327A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20305233.7 2020-03-05
EP20305233 2020-03-05
PCT/EP2021/055673 WO2021176090A1 (en) 2020-03-05 2021-03-05 Protease-processed molecules

Publications (1)

Publication Number Publication Date
AU2021231327A1 true AU2021231327A1 (en) 2022-10-27

Family

ID=71096648

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021231327A Pending AU2021231327A1 (en) 2020-03-05 2021-03-05 Protease-processed molecules

Country Status (15)

Country Link
US (1) US20230279151A1 (cg-RX-API-DMAC7.html)
EP (1) EP4114865B1 (cg-RX-API-DMAC7.html)
JP (1) JP7766608B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220150345A (cg-RX-API-DMAC7.html)
CN (1) CN115210265A (cg-RX-API-DMAC7.html)
AU (1) AU2021231327A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022017542A2 (cg-RX-API-DMAC7.html)
CA (1) CA3170452A1 (cg-RX-API-DMAC7.html)
DK (1) DK4114865T3 (cg-RX-API-DMAC7.html)
ES (1) ES3068539T3 (cg-RX-API-DMAC7.html)
IL (1) IL295958A (cg-RX-API-DMAC7.html)
MX (1) MX2022010958A (cg-RX-API-DMAC7.html)
PL (1) PL4114865T3 (cg-RX-API-DMAC7.html)
TW (1) TW202146463A (cg-RX-API-DMAC7.html)
WO (1) WO2021176090A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025199278A2 (en) * 2024-03-20 2025-09-25 Regeneron Pharmaceuticals, Inc. Masked multispecific antigen-binding molecules with cleavable linkers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060252096A1 (en) * 2005-04-26 2006-11-09 Glycofi, Inc. Single chain antibody with cleavable linker
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
CN103068846B9 (zh) * 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
CN112225798B (zh) * 2011-05-17 2023-07-18 洛克菲勒大学 人类免疫缺陷病毒中和抗体及其使用方法
EP2729488A4 (en) * 2011-07-06 2015-01-14 Medimmune Llc PROCESS FOR PREPARING MULTIMANT POLYPEPTIDES
KR101963230B1 (ko) * 2011-12-26 2019-03-29 삼성전자주식회사 복수개의 단일 항체를 포함하는 단백질 복합체
EP3197916A2 (en) * 2014-09-25 2017-08-02 Amgen Inc. Protease-activatable bispecific proteins
EP3443006B1 (en) 2016-04-13 2023-08-02 Sanofi Trispecific and/or trivalent binding proteins

Also Published As

Publication number Publication date
KR20220150345A (ko) 2022-11-10
ES3068539T3 (en) 2026-06-01
JP2023516380A (ja) 2023-04-19
US20230279151A1 (en) 2023-09-07
PL4114865T3 (pl) 2026-05-25
CA3170452A1 (en) 2021-09-10
BR112022017542A2 (pt) 2022-10-18
DK4114865T3 (da) 2026-04-27
CN115210265A (zh) 2022-10-18
JP7766608B2 (ja) 2025-11-10
IL295958A (en) 2022-10-01
MX2022010958A (es) 2022-10-07
TW202146463A (zh) 2021-12-16
EP4114865B1 (en) 2026-01-28
WO2021176090A1 (en) 2021-09-10
EP4114865A1 (en) 2023-01-11

Similar Documents

Publication Publication Date Title
CN113227124B (zh) 具有针对抗体的亲和性物质、切割性部分及反应性基团的化合物或其盐
ES2804450T3 (es) Método para la producción de dominios variables
CN108602878B (zh) C端赖氨酸缀合免疫球蛋白
KR102247704B1 (ko) 항 pd-1/항 her2 천연항체 구조 형태의 헤테로다이머 계의 이중특이성 항체 및 그 제조방법
AU2017279352B2 (en) Lysine conjugated immunoglobulins
US12433952B2 (en) Antibody-drug conjugates targeting folate receptor alpha and methods of use
JP2020512836A (ja) 抗pd−l1/抗pd−1天然抗体構造様ヘテロダイマー二重特異性抗体およびその調製方法
US20160152726A1 (en) Protein in which electrical interaction is introduced within hydrophobic interaction site and preparation method therefor
KR20200120648A (ko) 항pd-1/항her2 천연항체 구조 헤테로다이머계의 이중특이성 항체 및 그 제조방법
US20200369719A1 (en) Depletion of Light Chain Mispaired Antibody Variants By Hydrophobic Interaction Chromatography
CN119677543A (zh) 用于与抗体缀合的方法和工具
CN117242091A (zh) 半胱氨酸工程化抗体构建体、偶联物及使用方法
AU2026201242A1 (en) Bispecific antibodies with cleavable C-terminal charge-paired tags
CN119137154A (zh) 抗叶酸受体α抗体及使用方法
EP4114865B1 (en) Protease-processed molecules
TW202426058A (zh) 靶向磷脂醯肌醇蛋白聚糖-3之抗體-藥物結合物及使用方法
RU2846294C1 (ru) Молекулы, получаемые посредством процессинга протеазами
HK40087043A (en) Protease-processed molecules
HK40087043B (en) Protease-processed molecules
CN119343374A (zh) 新的掩蔽抗体
US20250346675A1 (en) Payload-bearing multispecific antibodies
HK40125045A (zh) 承载有效载荷的多特异性抗体
TW202547884A (zh) Muc16/napi-2b抗體及使用方法
TW202540163A (zh) 利用環境應答性胜肽的蛋白質之製造方法
KR20250111141A (ko) 단백질의 제조 방법